Pharmacokinetic consequences of a citalopram treatment discontinuation.
In this pilot study, the pharmacokinetics of citalopram (CIT) were examined in five hospitalized depressed patients after an abrupt discontinuation of a treatment with 40 mg/d of this selective serotonin reuptake inhibitor (SSRI). During the 8-day study period, clinical ratings were regularly carried out. Between days 5 and 8, the patients were treated with clomipramine (75 mg/d). The enantiomers of CIT and its metabolites, demethyl-CIT (DCIT) and CIT-propionic acid derivative (CIT-PROP), were measured repeatedly from day 0 to day 8 by a stereoselective high-performance liquid chromatography (HPLC) procedure. The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.
Voirol
P
P
University Department of Adult Psychiatry, Prilly-Lausanne, Switzerland.
Rubin
C
C
Bryois
C
C
Kosel
M
M
Buclin
T
T
Baumann
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015283:Citalopram / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002997:Clomipramine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013237:Stereoisomerism; D013375:Substance Withdrawal Syndrome
D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D002997:Clomipramine; D017367:Selective Serotonin Reuptake Inhibitors